The European Commission has granted Novo Nordisk marketing authorizations for Tresiba (insulin degludec) and Ryzodeg (in…
Insulin
Novo Nordisk’s Combination Insulin Ryzodeg Approved in Japan
The Japanese Ministry of Health, Labor and Welfare has approved Novo Nordisk's new combination insulin, Ryzodeg, for the…
Degludec, Novo Nordisk’s New Insulin, On Its Way To FDA Approval
The Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) comple…
EU Panel Backs Novo Nordisk’s Tresiba
The Committee for Medicinal Products for Human Use (CHMP) under the European Medicines Agency (EMA) adopted positive opi…
Hypoglycemia Common Among Type 2 Diabetes Patients Treated with Insulin
According to the GAPP2™ (Global Attitudes of Patients and Physicians) survey, funded by Novo Nordisk and presented today…
Lantus Insulin More Effective in Achieving Long Term Blood Sugar Control in Type 2 Diabetes Patients
New results presented by Sanofi at European Association for the Study of Diabetes (EASD) 48th Annual Meeting showed trea…
Novo Nordisk’s New Ultra-Long-Acting Insulin Degludec Shows Lower Rate of Hypoglycemia
Data from two new studies shows patients with type 2 diabetes starting insulin therapy had a 43% lower rate of night-tim…
Novo Nordisk’s Ultra-Long Acting Insulin, Tresiba, Approved in Japan
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk's ultra-long acting insulin, insulin deglu…
Biodel Initiates a Phase 2 Study of Ultra-Rapid-Acting Insulin
Biodel has initiated a Phase 2 clinical trial of its proprietary recombinant insulin (RHI)-based ultra-rapid-acting meal…
NIH Awards Biodel Grant to Develop Ultra-Rapid-Acting Insulin for Use in Artificial Pancreas
The Small Business Innovation Research (SBIR) program of the National Institutes of Health (NIH) has awarded Biodel a gr…
